Hari Kumar

Hari Kumar

Chairman chez Kinarus AG

69 ans
Health Technology
Consumer Services
Commercial Services

Profil

Hari Kumar is currently the Chairman at Kinarus AG, Chairman at Kinarus Therapeutics Holding AG, Director at Bullet Biotechnology, Inc., and Director at Translational Research In Oncology.
Previously, he served as the Chief Executive Officer & Director at Adheron Therapeutics, Inc. and Panmira Pharmaceuticals LLC, Independent Director at CymaBay Therapeutics, Inc., Director-European Marketing at Eisai Ltd.
(United Kingdom), Independent Director at BioVie, Inc., Director-Global Business Development at Hoffmann-La Roche, Inc., Global Head-Transplant Immunosuppressives at Roche Pharmaceuticals, Inc., and Chief Business Officer at Amira Pharmaceuticals, Inc. He received his undergraduate degree from the University of Malaya and his doctorate from the University of London in 1984.

Postes actifs de Hari Kumar

SociétésPosteDébut
Director/Board Member -
Translational Research In Oncology Director/Board Member 01/02/2020
Chairman 26/04/2021
Tous les postes actifs de Hari Kumar

Anciens postes connus de Hari Kumar

SociétésPosteFin
Sales & Marketing 01/01/1999
KINARUS THERAPEUTICS HOLDING AG Chairman -
Corporate Officer/Principal -
BIOVIE INC. Director/Board Member -
CYMABAY THERAPEUTICS, INC. Director/Board Member -
Voir l'expérience en détail de Hari Kumar

Formation de Hari Kumar

University of Malaya Undergraduate Degree
University of London Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Hari Kumar

Relations

100 +

Relations au 1er degré

14

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées1
BIOVIE INC.

Health Technology

Entreprise privées11

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Translational Research In Oncology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Hari Kumar